MGI PHARMA's SALAGEN FOR RADIATION-INDUCED DRY MOUTH IS "APPROVABLE"
MGI PHARMA's SALAGEN FOR RADIATION-INDUCED DRY MOUTH IS "APPROVABLE" at FDA, the Minneapolis-based company announced Dec. 29. Salagen, the first systemic formulation of pilocarpine, is a treatment for xerostomia, or chronic dry mouth, caused by radiation therapy for head and neck cancers. Xerostomia causes pain, difficulty eating, sleeping and talking, as well as rapid tooth decay. MGI Pharma submitted the NDA for Salagen in February 1992.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth